CanSino Biologics Inc. Just Missed Earnings - But Analysts Have Updated Their Models
It's been a good week for CanSino Biologics Inc. (HKG:6185) shareholders, because the company has just released its latest quarterly results, and the shares gained 9.3% to HK$29.50. Statutory earnings per share disappointed, coming in -22% short of expectations, at CN¥0.16. Fortunately revenue performance was a lot stronger at CN¥356m arriving 14% ahead of predictions. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Following the latest results, CanSino Biologics' three analysts are now forecasting revenues of CN¥1.43b in 2026. This would be a meaningful 15% improvement in revenue compared to the last 12 months. Before this earnings report, the analysts had been forecasting revenues of CN¥1.43b and earnings per share (EPS) of CN¥0.58 in 2026. So we can see that while the consensus made no real change to its revenue estimates, it also no longer provides an earnings per share estimate. This suggests that revenues are what the market is focusing on after the latest results.
Check out our latest analysis for CanSino Biologics
There's been no real change to the consensus price target of HK$48.28, with CanSino Biologics seemingly executing in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on CanSino Biologics, with the most bullish analyst valuing it at HK$53.16 and the most bearish at HK$44.17 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting CanSino Biologics is an easy business to forecast or the the analysts are all using similar assumptions.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. One thing stands out from these estimates, which is that CanSino Biologics is forecast to grow faster in the future than it has in the past, with revenues expected to display 33% annualised growth until the end of 2026. If achieved, this would be a much better result than the 33% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 21% per year. Not only are CanSino Biologics' revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.
The Bottom Line
The most important thing to take away is that the analysts reconfirmed their revenue estimates for next year, suggesting that the business is performing in line with expectations. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at HK$48.28, with the latest estimates not enough to have an impact on their price targets.
We have estimates for CanSino Biologics from its three analysts out to 2028, and you can see them free on our platform here.
Plus, you should also learn about the 2 warning signs we've spotted with CanSino Biologics .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.